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Abstract
Background: Patients with heightened platelet reactivity in response to antiplatelet agents are at an increased risk
of recurrent ischemic events. However, there is a lack of diagnostic criteria for increased response to combined
aspirin/clopidogrel therapy. The challenge is to identify patients at risk of bleeding. This study sought to
characterize bleeding tendency in patients treated with aspirin and clopidogrel.
Patients/methods: In a single-center prospective study, 100 patients under long-term aspirin/clopidogrel
treatment, the effect of therapy was assayed by template bleeding time (BT) and the inhibition of platelet
aggregation (IPA) by light transmission aggregometry (LTA). Arachidonic acid (0.625 mmol/L) and adenosine
diphosphate (ADP; 2, 4, and 8 μmol/L) were used as platelet agonists.
Results: Bleeding episodes (28 nuisance, 2 hematuria [1 severe], 1 severe proctorrhagia, 1 severe epistaxis) were
significantly more frequent in patients with longer BT. Template BT ≥ 24 min was associated with bleeding
episodes (28 of 32). Risk of bleeding increased 17.4% for each 1 min increase in BT. Correlation was found between
BT and IPAmax in response to ADP 2 μmol/L but not to ADP 4 or 8 μmol/L.
Conclusion: In patients treated with dual aspirin/clopidogrel therapy, nuisance and internal bleeding were
significantly associated with template BT and with IPAmax in response to ADP 2 μmol/L but not in response to
ADP 4 μmol/L or 8 μmol/L.
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Introduction
Until recently, long-term antiplatelet therapy for the pre-
vention of atherothrombotic disease was limited to
aspirin (ASA). The availability of thienopyridines, parti-
cularly clopidogrel (CLOP), represented an important
addition to the physician’s armamentarium. The combi-
nation of CLOP and ASA in patients with acute coronary
syndrome (ACS) reduces the risk of reinfarction, stroke,
and death by 20% compared with ASA alone [1]. Never-
theless, the current therapy options for these patients are
suboptimal. Despite the use of available antiplatelet
therapies, the recurrence of ischemic events in patients
with ACS is still increasing and bleeding remains an
important, and often underappreciated, risk with these
therapies. Patient noncompliance because of bleeding
contributes to thrombosis events.
The exact mechanism of benefit has not yet been eluci-
dated but is clearly related not just to inhibition of platelet
aggregation (IPA) but also to modification of the many
consequences of the platelet activation-endothelial rela-
tionships [2]. The current gold standard for testing platelet
function is light transmission platelet aggregometry (LTA),
which is used to categorize patients receiving ASA and/or
CLOP therapy as responders or nonresponders.
Several published studies deal with low platelet respon-
siveness, the diagnosis of platelet resistance or platelet
failure [3] and show that patients with heightened platelet
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increased risk of recurrent ischemic events, particularly
when they undergo percutaneous coronary intervention
[4-6].
But the clear challenge of responsiveness to ASA, CLOP,
and other thienopyridine derivatives is to identify the
patients at risk of bleeding who will benefit from antiplate-
let therapy without hemorrhagic complications. Effective-
ness (thrombosis prevention) with adequate safety (no or
few hemorrhagic events) is an unresolved clinical problem,
and the issue remains constrained by considerable differ-
ences between testing methods. A potential association
between platelet response and bleeding in patients on
combined therapy of aspirin and clopidogrel undergoing
coronary stent placement [7] and in other clinical situa-
tions [8] has been reported.
This prospective observational study was designed to
determine the relationship between template bleeding
time (BT) and bleeding complications in patients receiving
ASA and CLOP. We also sought to determine if there is a
correlation between BT and IPA through LTA studies of
platelet-rich plasma (PRP).
Methods
Patients
We enrolled 109 patients (67 men, 42 women) who were
referred to our Thrombosis Center for thrombophilia
screening. Nine patients were excluded at entry (5 men, 4
women): 3 because of a history of superficial or nuisance
bleeding, 1 because of von Willebrand disease, 1 because
of essential thrombocytemia, 1 with ischemic optical neur-
itis, 1 with Raynaud syndrome, and 2 with amaurosis
fugax, Thus, 100 patients treated with dual antiplatelet
therapy, indicated by their own physician (81-100 mg ASA
daily and 75 mg CLOP daily), were included in the study.
This study was approved by the review board and all parti-
cipants provided informed consent before being enrolled
in the study.
The study participants included 62 men and 38 women,
mean age 61.4 (SD ± 11.8) years, median age 62 years,
range 35-83 years) with no history of hemorrhagic diseases
referred because of previous vascular cerebral symptoma-
tology (1 stroke, 19 transient ischemic events, 17 with
ischemic cerebral focus by nuclear magnetic resonance),
myocardial infarction or coronary artery bypass graft (n =
14), one or multiple coronary stents (n = 46, 38 coronary
drug-eluting stents), and peripheral arterial disease (n =3 ) .
Bleeding was defined according to Ben-Dor et al. [9]:
alarming bleeding, internal bleeding, and nuisance bleed-
ing. Internal bleeding included hematoma, epistaxis, vagi-
nal bleeding, melena, hematemesis, eye bleeding, and
haematuria. Nuisance bleeding included easy bruising,
bleeding from small cuts, petechia, and ecchymosis and
was assessed during routine clinical follow-up. Only one
bleeding episode was recorded for each patient.
Additional Medical Therapy
Most patients were receiving additional therapy at the
time of the study: antidepressants (n = 6), antidiabetics
(n = 11), anxiolytics (n = 26), beta-blockers (n =3 6 ) ,
ACE inhibitors (n = 23), folic acid (n = 11), lipid-lower-
ing agents (n = 53), protein pump inhibitor (PPI) (n =
16, 7 on omeprazol), levothyroxine (n = 7), and diuretics
(n = 3). Drug-drug interaction between the PPI omepra-
zole and CLOP that attenuates the antiplatelet effect has
been described recently but is not yet widely accepted
[10-13]; the US Food and Drug Administration has
alerted the public to new safety information concerning
an interaction between the 2 therapies. Because of these
contradicting publications and, to the best of our knowl-
edge, the absence of any publications showing that PPI
drugs affect BT, patients receiving omeprazole therapy
w e r en o te x c l u d e df r o mt h es t u d y .N o n eo ft h ep a t i e n t s
were receiving anticoagulant therapy.
Patients presented several comorbidities including dia-
betes (11%), hypertension (57%), and dyslipidemia (53%);
5% had peripheral vascular disease. No patients were
active smokers. The mean number of weeks on clopido-
grel + aspirin was 28.3 ± 10.6 weeks (max 58 weeks,
min 12 weeks).
Hemostasis Tests and Bleeding Time
Venous blood was drawn from the antecubital vein with-
out stasis and mixed with 0.11 mol/L sodium citrate
(1:10 v/v). PRP was obtained by centrifugation at 150 ×g
for 10 min at room temperature; platelet-poor plasma
(PPP) was obtained by centrifugation of PRP at 900 ×g
for 15 min at 20°C. The PRP was adjusted to a platelet
count of 290,000-310,000/μL with autologous PPP. If
contamination of the PRP with erythrocytes or leukocytes
was observed by light microscopy, a second centrifuga-
tion at 900 ×g for 5 min was carried out to minimize the
cell number. Plastic syringes, tubes, and pipettes were
used for all tests. LTA of the PRP was performed in a
double-channel Lumi-Aggregometer (Chrono-log Corp.,
Havertown, PA, USA). Light transmission was set at 10%
for PRP and 90% for PPP. The aggregating agent (1-10
μL) was added to PRP in the aggregometer at 37°C with
constant stirring (1000 rpm). Arachidonic acid (AA)
sodium salt (0.625 mmol/L; Sigma, St. Louis, MO, USA)
and adenosine diphosphate (ADP; 2, 4, and 8 μmol/L;
Sigma, St. Louis, MO, USA) were used as platelet ago-
nists in the aggregation studies. The percentage IPA was
expressed as 100% minus the maximal percent change in
light transmission from baseline with PPP used as a
reference.
Altman et al. Thrombosis Journal 2012, 10:3
http://www.thrombosisjournal.com/content/10/1/3
Page 2 of 7For BT, a disposable Surgicutt adult device (ITC, Thora-
t e cC o ,E d i s o n ,N J ,U S A )w a su s e dt om a k eas t a n d a r d
incision (5-mm long, 1-mm deep) on the volar surface of
the forearm, perpendicular to the antecubital crease, while
maintaining a pressure of 40 mmHg in a sphygmoman-
ometer cuff. The time until complete cessation of bleeding
(to the nearest 30 s) was recorded as the BT. Bleeding was
followed for a maximum of 26 min. The BT and analysis
of platelet function were performed in the morning of the
same day.
Basic hemostasis studies, prothrombin time, activated
partial prothrombin time, and platelet count were per-
formed at entry. Other tests exploring hemostasis were
performed when indicated. Platelet function analyses were
performed in accordance with a standardized protocol by
the same trained technician, who was not aware of the
study objectives or drug intake.
Statistical Analysis
The nature of the quantitative variable distribution was
evaluated by the Shapiro-Wilk test. Differences among
groups of quantitative data were explored by ANOVA
(Bonferroni post hoc test) or Kruskal-Wallis test in corre-
spondence with the distribution of the variables. Differ-
ences among groups in terms of the frequency of patients
reporting nuisance bleeding were evaluated by the chi-
square test. Correlation between BT and IPA was explored
using the Spearman rank order method. The association
between nuisance bleeding and quantitative variables, such
as BT and IPA, was studied using receiver operating
curves (ROC) by obtaining the corresponding area under
the curve (AUC) values and their standard errors. Cutoff
points were also obtained. The multivariate association
between bleeding and BT, (adjusted for gender, age, and
IPA) was explored by multiple logistic regression (maxi-
mum likelihood; quasi-Newton). Significance was set at
P <0 . 0 5 .
Results
In our population, the mean BT was 21.5 ± 6.2 min, ran-
ging from 4 min to more than 26 min. The incidence of
bleeding was 32%. Fifty-two patients had a BT longer than
26 min: 21 nuisance bleeding, 2 internal bleeding (1 severe
hematuria, 1 epistaxis), and 1 alarming bleeding (proctor-
rhagia with life compromise requiring transfusion). Seven-
teen patients had a BT longer than 20.5 min and less than
26 min: 5 nuisance bleeding and 1 internal bleeding (mild
hematuria) which stopped after discontinuation of platelet
inhibitory agents.
The PRP was activated with 0.625 mmol/L AA or 2, 4,
or 8 μmol/L ADP. The maximal aggregation at each
agonist concentration was taken as the IPA for the
calculations.
The IPA resulting from the maximal AA-induced LTA
was not different among patients with or without bleed-
ing episodes (Table 1). As expected, there was
an inverse correlation between ADP concentration and
IPAmax. The Spearman rank order method showed
a weak significant correlation between BT and IPAmax
(correlation between BT and ADP 2 μmol/L, r = 0.32,
P = 0.001; between BT and ADP 4 μmol/L, r =0 . 3 1 ,
P = 0.002; between BT and ADP 8 μmol/L, r =0 . 3 8 ,
P = 0.0002).
I nt h eu n i v a r i a t ea n a l y s i s( T a b l e2 ) ,b l e e d i n ge v e n t s
correlated significantly with BT (17% of risk increase per
minute of BT, P = 0.004) and with ADP 2 μmol/L (4% of
risk increase per μmol/L, P = 0.049). No correlation was
found between bleeding and IPAmax in response to ADP
4 μmol/L or 8 μmol/L. ROC analysis (Table 3) also
demonstrated that bleeding events correlated signifi-
cantly with BT and with IPAmax in response to ADP 2
μmol/L but not in response to ADP 4 μmol/L or 8 μmol/
L. According to the ROC, 24 min appears to be the cutoff
above which bleeding events are more frequent. In the
multivariate logistic analysis, risk for nuisance bleeding
was significantly associated with BT (after adjustment for
age, gender and ADP2 max values). The multivariate OR
was 1.16 per min (95%CI: 1.04-1.30).
Discussion
Besides hyporesponsiveness to CLOP and other thieno-
pyridine derivatives, the clear challenge of antithrombotic
therapy is to identify the patients at risk of bleeding who
will benefit from antiplatelet therapy without hemorrha-
gic complications. New data from a study by Shehab et
al. [8] showed a substantial risk of bleeding with dual
therapy of aspirin plus clopidogrel in a real-world setting.
This study was carried out on patients with vascular
pathology or a coronary stent device under prolonged
antiplatelets drugs to test the dual therapy effect through
LTA and template bleeding time. Ideally, comparing vari-
ables measured before and after treatment allows the
effect of therapy in each patient to be determined, but
Table 1 Mean value (± SD) of BT and IPAmax in the
study population in response to AA and to different
concentrations of ADP
Variable
Follow-up, weeks, (mean ± SD) 28.3 ± 10.6
Bleeding time, min (mean ± SD) 21.5 ± 6.2
AA 0.625 mmol/L IPAmax %(mean ± SD) 96.2 ± 4.5
ADP 2 μmol/L IPAmax % (mean ± SD) 75.6 ± 13.5
ADP 4 μmol/L IPAmax % (mean ± SD) 69.4 ± 13.4
ADP 8 μmol/L IPAmax % (mean ± SD) 65.0 ± 13.3
Incidence of bleeding (%) 32
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with antithrombotic drugs is difficult because patients
usually receive treatment very early, before it is possible
to perform hemostasis tests. There is no agreement on
how responsiveness should be measured concerning
devices and cutoff values [14-19].
In the current study, among the 100 patients included
in the follow-up, 28 patients had nuisance bleeding, 2
patients had haematuria 1 had proctorrhagia, and 1
patient had epistaxis. Twenty-five patients with nuisance
bleeding and the patients with haematuria, epistaxis, and
proctorrhagia had longer BT. Twenty-eight of the 32
patients with bleeding episodes had a template BT ≥ 24
min. The univariate analysis and ROC AUC showed that
the bleeding events correlated with BT and with ADP 2
μmol/L. In the multiple logistic regression model (risk
for nuisance bleeding of BT adjusted by ADP 2 μmol/L,
IPAmax (% values)) significant correlation between BT
and bleeding events was found (odds ratio (OR) per min-
ute, 1.16 (95% confidence interval (CI) 1.04-1.30, P =
0.007). Moreover ≥ 24 min appears to be the cutoff above
which nuisance bleeding or severe bleeding is more
frequent.
The BTs were compared with regard to platelet aggre-
gation. The IPA is derived from the maximal aggregation
obtained in the LTA of PRP. The IPAmax in AA-acti-
vated PRP and ADP 4 and 8 μmol/L did not discriminate
patients with bleeding tendency. The IPAmax in response
to ADP 2 μmol/L does seem to be sensitive for predicting
bleeding episodes in patients receiving ASA plus CLOP
treatment.
The BT, as well as LTA, is considered to be an inaccu-
rate and poorly reproducible technique, which is depen-
dent on several variables. Therefore, these methods could
be inappropriate for measuring platelet inhibition activity
[20,21]. Nevertheless, LTA is the gold standard test of
platelet function and is used to categorize patients receiv-
ing ASA, CLOP, or dual therapy as responders or nonre-
sponders or to define drug resistance. In addition, a
recent paper used LTA to compare IPA between patients
receiving ticagrelor or CLOP therapy [22]. Antonino et
al. [23] found a strong correlation (P ≤ 0.04) between
LTA and flow cytometric measurements. Gremmel et al.
[24] found that the results from 4 different assays of pla-
telet function significantly correlated with LTA, and
P a n i c c i ae ta l .[ 2 5 ]f o u n das i g n i f i c a n tc o r r e l a t i o n
between LTA and VerifyNow but not the PFA-100 assay.
Recently, Bonello et al. [26] provided a consensus opinion
on the definition of high on-treatment platelet reactivity
to ADP based on various methods reported in the litera-
ture and proposed LTA as 1 of the 4 tests associated with
clinical risk. Very recently, Parodi et al. [5] found that
high residual platelet reactivity assessed by LTA and
ADP as agonist among patients receiving clopidogrel
after percutaneous coronary intervention (PCI) has been
associated with a high risk of ischemic events at short-
and long-term follow-up.
Breet et al. [20] reported that LTA and 5 other assay
methods available for platelet studies were unable to pre-
dict which patients were at higher risk of bleeding follow-
ing stent implantation. In contrast, Tsukahara et al. [27]
found that high platelet responsiveness to CLOP or ticlo-
pidine plus ASA, using LTA and ADP as an agonist, is
associated with an increased risk of bleeding. Serebruany
et al. [28] found that inhibition of platelet aggregation >
50% using 5 μM ADP-induced IPA strongly correlates
with minor but not severe bleeding events in a large
cohort of patients with coronary artery disease and
ischemic stroke treated with chronic low-dose aspirin plus
clopidogrel.
Cuiset et al. [29] identified patients post-treatment as
hyper-responders when ADP-induced platelet aggregation
was below < 40% (IPA > 60%). The risk of TIMI major
and minor bleeding was significantly higher in these
patients.
N o n eo ft h e s es t u d i e s ,a l t h o u g ht h e yi n c l u d eal a r g e
number of patients, deals with BT, the only in vivo test
that detects the relationship between vascular endothelium
and platelets.
Template BT is an invasive technique displaying low
sensitivity to mild or moderate abnormalities of inherited
platelet defects. The situation may be different when the
effects of drugs are being tested. According to our results,
when BT is carried out by experienced personnel, it is a
useful technique for evaluating the in vivo effects of anti-
platelet agents. Although a number of other platelet func-
tion tests have been developed subsequent to BT [30],
these tests have shown poor correlation and agreement
Table 3 Association between BT, IPAmax values and
nuisance bleeding: ROC AUC
Quantitative variable ROC AUC 95%CI for AUC P value
BT (min) 0.695 0.595-0.783 0.0009
ADP 2 μmol/L IPA max (%) 0.631 0.529-0.725 0.0330
ADP 4 μmol/L IPA max (%) 0.597 0.495-0.694 0.1170
ADP 8 μmol/L IPA max (%) 0.565 0.462-0.663 0.3016
Table 2 Univariate associations between BT, IPAmax
values in response to ADP (independent covariates) and
nuisance bleeding (end point): logistic regression
Variables Odds ratio 95% CI P value
BT (per min) 1.17 1.05-1.31 0.0035
ADP 2 μmol/L IPAmax % 1.04 1.00-1.08 0.0488
ADP 4 μmol/L IPAmax % 1.03 0.99-1.07 0.0876
ADP 8 μmol/L IPAmax % 1.02 0.98-1.06 0.2102
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classifying patients remains undetermined [31,32].
In some circumstances, the cessation of ASA/CLOP
treatment (eg, a drug-eluting stent in patients under-
going PCI) is a strong risk factor for thrombosis. Several
published studies have shown that patients exhibiting
heightened platelet reactivity (ie, low IPA) to antiplatelet
agents might be at increased risk of recurrent ischemic
events, particularly when they undergo PCI [33-35].
Nevertheless, prediction of bleeding in individual
patients remains a challenge.
The important question is whether an antiplatelet agent
has the desired effectiveness (ie, thrombosis prevention)
with adequate safety (ie, few or no hemorrhagic events).
What becomes a problem for the patients is even minor
or moderate bleeding, as shown by Rao et al. [36] who
pooled the data from 4 multicenter, randomized clinical
trials of patients with ACS.
The GUSTO bleeding classification was found to iden-
tify patients at risk of short- and long-term death and
myocardial infarction. Even though Aronow et al. [37] did
not find a significant increase in the overall rate of major
or minor thrombolysis in myocardial infarction TIMI
score bleeding in patients after PCI when adding CLOP to
ASA, major gastrointestinal bleeding increased in the year
after PCI. Nuisance bleeding is commonly encountered in
patients taking dual antiplatelet therapy, and its incidence
and impact are important for compliance. Roy et al. [38]
found that 32.4% reported bleeding events, of which 85.7%
were nuisance, 13.6% were internal, and 0.7% were alarm-
ing. In the nuisance bleeding group, the rate of CLOP dis-
continuation was 11.1%.
According to our results in the present study, template
BT indicates which patients are prone to bleeding with
combined ASA/CLOP therapy, and there is correlation
between BT and IPAmax in response to low concentration
of ADP (2 μmol/L) but not at higher concentrations (4 or
8 μmol/L). This finding is not surprising because BT is
indicative of the platelet-endothelial cell interactions and
platelet aggregation is indicative of platelet-platelet
interactions
The initial step in primary hemostasis is the adhesion of
platelets to the subendothelial matrix through specific
adhesive glycoproteins. The deposition of platelets on the
subendothelium involves the platelet receptor GP Ib/IX/V
complex, which interacts with the high molecular weight
multimeric plasma protein von Willebrand factor. GPIIb/
IIIa (integrin aIIbb3), which links activated platelets
through fibrinogen bridges, is the central platelet receptor
in aggregation supporting platelet-platelet interactions.
The stimulation of platelets as a result of adhesion leads to
a spreading activation of GPIIb/IIIa, enabling the binding
of soluble fibrinogen, leading to platelet aggregation and
granule secretion [39]. Although interconnected, platelet
adhesion and aggregation are different steps in hemostasis,
and drugs used therapeutically as antithrombotic agents
could affect platelet adhesion, platelet aggregation, or
both. Aspirin acts by irreversibly acetylating platelet
cyclooxygenase-1, thereby blocking the formation of
thromboxane A2. Clopidogrel acts by blocking the P2Y12
platelet ADP receptor, thereby inhibiting ADP-induced
platelet activation and aggregation. The IPA is probably
not the exact mechanism of the benefit of ASA and CLOP
because of the effect on the many consequences of platelet
activation-endothelial relationships [40].
As a result of combining ASA and CLOP, template
BT was prolonged (≥ 26 min) in 55 of 100 patients
(55%); it is pretty clear that this antiplatelet combination
affects not only platelet aggregation and thrombin gen-
eration [41] but also platelet-endothelial cell interac-
tions, modifying primary hemostasis. This modification
could be an important, perhaps the most important,
effect for thrombosis prevention. Increasing evidence
indicates that platelet adhesion is involved in the earliest
development of atherosclerotic lesions [42].
In conclusion, although platelet hyporesponsiveness to
CLOP has been associated with major adverse cardio-
vascular events and stent thrombosis, the risk of
increased platelet inhibition is bleeding, which has been
strongly linked to mortality [43]. We found that, in
patients taking ASA plus CLOP who had a prolonged
template BT, bleeding events were frequent. Template
BT determined by a trained technician could be useful
for following patients treated with dual antiplatelet ther-
apy. Among these patients, those with BT ≥ 24 min pre-
sented with increased bleeding episodes (nuisance
bleeding, epistaxis, hematuria, and proctorrhagia). More-
over, we found correlation between bleeding events and
IPAmax in response to feeble concentrations of ADP 2
μmol/L in LTA, consistent with the hypothesis that
lower IPA in response to ADP is associated with
increased bleeding risk, but definitive studies are neces-
sary to determine the cutoff point of reactivity to ADP
associated with bleeding risk. The present results may
have greater relevance with the emergence of more
potent antiplatelet drugs [44].
The main limitation of our results is the sample size
but the statistical differences in BT between patients
with no bleeding and patients with bleeding risk support
our findings; a larger study is indicated.
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